{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:03:15Z","timestamp":1789963395709,"version":"4.0.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with Alzheimer\u2019s disease (AD) with a low to intermediate tau-PET burden might benefit most from anti-amyloid treatment. Staging tau burden with plasma biomarkers would offer a scalable alternative to staging with tau-PET. This study investigated whether key plasma biomarkers P-tau217, P-tau181, A\u03b242\/40, GFAP and NfL can be used to accurately stage amyloid status (A-\/A+) and tau-PET burden, and evaluated the relation of such a plasma-based staging system with cognitive outcomes over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included 105 participants with subjective cognitive decline (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927\u00a0A-,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918 A+), A+ mild cognitive impairment (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910) or A\u2009+\u2009AD-dementia (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200950) from the Amsterdam Dementia Cohort who underwent [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir PET-burden assessment (T\n                      <jats:sub>low<\/jats:sub>\n                      , T\n                      <jats:sub>intermediate<\/jats:sub>\n                      or T\n                      <jats:sub>high<\/jats:sub>\n                      ; based on MUBADA SUVr) and longitudinal cognitive assessment (average follow-up: 4.1\u2009\u00b1\u20093.5 years). AD-related plasma biomarkers were measured with Simoa. Discriminative performance (AUC) of each marker was compared using ROC analysis, and combined utility was assessed with logistic regression. Subsequently, cutoffs were established aiming for 90%-specificity, to regroup participants into a plasma-based staging scheme. Age-, sex- and education-adjusted linear mixed models (LMM) were performed to compare associations of plasma versus PET-based staging with longitudinal cognition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      27 participants were A-T\n                      <jats:sub>PET_low<\/jats:sub>\n                      , 22\u00a0A+T\n                      <jats:sub>PET_low<\/jats:sub>\n                      , 27\u00a0A+T\n                      <jats:sub>PET_int<\/jats:sub>\n                      and 29\u00a0A+T\n                      <jats:sub>PET_high<\/jats:sub>\n                      . To discriminate A-T\n                      <jats:sub>PET_low<\/jats:sub>\n                      participants from A+T\n                      <jats:sub>PET_low\/int<\/jats:sub>\n                      participants, P-tau217 performed best among all measured markers P-tau217, P-tau181, A\u03b242\/40, GFAP and NfL (AUC\u2009=\u20090.92 [95% CI: 0.856\u20130.985]). To discriminate A+T\n                      <jats:sub>PET_high<\/jats:sub>\n                      participants from A+T\n                      <jats:sub>PET_low\/int<\/jats:sub>\n                      participants, also P-tau217 performed best among all markers (AUC\u2009=\u20090.74 [95% CI: 0.618\u20130.862]). A combination of Wald\u2019s backward-selected plasma markers did not statistically improve discriminative performance (DeLong\u2019s\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05; two-marker combinations selected). Applying two cutoffs for P-tau217 as well as for the two-marker combinations, at 90% specificity to discriminate subsequent groups, we derived two plasma-based staging schemes. While the tau-PET staging scheme significantly and consistently associated with cognitive performance and decline across cognitive domains in LMMs, the plasma staging schemes did not.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Performance of plasma-based staging approaches developed in this study were high when discriminating individuals without amyloid pathology, while this was moderate when discriminating amyloid positive individuals with a high tau-PET burden. Our LMM findings visualize that tau staging in amyloid-positive individuals remains optimally performed with tau-PET scans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-026-02085-6","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:18:02Z","timestamp":1782789482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The potential of key Alzheimer\u2019s plasma biomarkers to mimic tau PET MUBADA-based disease staging"],"prefix":"10.1186","volume":"18","author":[{"given":"Inge M. W.","family":"Verberk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte A.","family":"de Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Coomans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Trieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Leeuwis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Honigberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everard G. B.","family":"Vijverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsmarieke","family":"van de Giessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"2085_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr., et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"2085_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, et al. Alzheimer\u2019s disease. Lancet. 2021;397:1577\u201390.","journal-title":"Lancet"},{"key":"2085_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, et al. Donanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"2085_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2022","unstructured":"van Dyck CH, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2022;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"2085_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"2085_CR6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll M, et al. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron. 2016;89:971\u201382.","journal-title":"Neuron"},{"key":"2085_CR7","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/brain\/awab248","volume":"144","author":"TA Pascoal","year":"2021","unstructured":"Pascoal TA, et al. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. Brain. 2021;144:3517\u201328.","journal-title":"Brain"},{"key":"2085_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","volume":"2","author":"J Therriault","year":"2022","unstructured":"Therriault J, et al. Biomarker modeling of Alzheimer\u2019s disease using PET-based Braak staging. Nat Aging. 2022;2:526\u201335.","journal-title":"Nat Aging"},{"key":"2085_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s43587-024-00599-y","volume":"4","author":"G Salvad\u00f3","year":"2024","unstructured":"Salvad\u00f3 G, et al. Disease staging of Alzheimer\u2019s disease using a CSF-based biomarker model. Nat Aging. 2024;4:694\u2013708.","journal-title":"Nat Aging"},{"key":"2085_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21:66\u201377.","journal-title":"Lancet Neurol"},{"key":"2085_CR11","doi-asserted-by":"publisher","first-page":"e14408","DOI":"10.15252\/emmm.202114408","volume":"14","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, et al. Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Mol Med. 2022;14:e14408.","journal-title":"EMBO Mol Med"},{"key":"2085_CR12","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2022;18:2669\u201386.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2085_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","volume":"81","author":"N Mattsson-Carlgren","year":"2024","unstructured":"Mattsson-Carlgren N, et al. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies. JAMA Neurol. 2024;81:69\u201378.","journal-title":"JAMA Neurol"},{"key":"2085_CR14","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/brain\/awad042","volume":"146","author":"CR Jack","year":"2023","unstructured":"Jack CR, et al. Predicting amyloid PET and tau PET stages with plasma biomarkers. Brain. 2023;146:2029\u201344.","journal-title":"Brain"},{"key":"2085_CR15","doi-asserted-by":"publisher","first-page":"105405","DOI":"10.1016\/j.ebiom.2024.105405","volume":"109","author":"A Feizpour","year":"2024","unstructured":"Feizpour A, et al. Detection and staging of Alzheimer\u2019s disease by plasma pTau217 on a high throughput immunoassay platform. eBioMedicine. 2024;109:105405.","journal-title":"eBioMedicine"},{"key":"2085_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13195-023-01302-w","volume":"15","author":"NS Mundada","year":"2023","unstructured":"Mundada NS, et al. Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment. Alzheimers Res Ther. 2023;15:157.","journal-title":"Alzheimers Res Ther"},{"key":"2085_CR17","doi-asserted-by":"publisher","first-page":"e71199","DOI":"10.1002\/alz.71199","volume":"22","author":"H-K Kim","year":"2026","unstructured":"Kim H-K, et al. Plasma p-tau217 predicts PET-based pathological staging for precision Alzheimer disease assessment. Alzheimer\u2019s Dement. 2026;22:e71199.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2085_CR18","doi-asserted-by":"crossref","unstructured":"Montoliu-Gaya L et al. Plasma tau biomarkers for biological staging of Alzheimer\u2019s disease. Nat Aging. 2025;5:2297\u20132308.","DOI":"10.1038\/s43587-025-00951-w"},{"key":"2085_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/JAD-132306","volume":"41","author":"WM van der Flier","year":"2014","unstructured":"van der Flier WM, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41:313\u201327.","journal-title":"J Alzheimers Dis"},{"key":"2085_CR20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. J Alzheimers Dis. 2018;62:1091\u2013111.","journal-title":"J Alzheimers Dis"},{"key":"2085_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-018-0390-y","volume":"10","author":"RER Slot","year":"2018","unstructured":"Slot RER, et al. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimers Res Ther. 2018;10:76.","journal-title":"Alzheimers Res Ther"},{"key":"2085_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2967\/jnumed.122.264279","volume":"64","author":"EM Coomans","year":"2023","unstructured":"Coomans EM, et al. A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer\u2019s Disease Continuum. J Nucl Med. 2023;64:437\u201343.","journal-title":"J Nucl Med"},{"key":"2085_CR23","doi-asserted-by":"crossref","unstructured":"Verberk IMW et al. Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice. Alzheimers Dement. 2024;20:6115-6132.","DOI":"10.1002\/alz.14088"},{"key":"2085_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"2085_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"2085_CR26","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10:844\u201352.","journal-title":"Alzheimers Dement"},{"key":"2085_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13195-019-0532-x","volume":"11","author":"A de Wilde","year":"2019","unstructured":"de Wilde A, et al. Discordant amyloid-beta PET and CSF biomarkers and its clinical consequences. Alzheimers Res Ther. 2019;11:78.","journal-title":"Alzheimers Res Ther"},{"key":"2085_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-016-0228-4","volume":"9","author":"MD Zwan","year":"2017","unstructured":"Zwan MD, et al. Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9:2.","journal-title":"Alzheimers Res Ther"},{"key":"2085_CR29","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1212\/WNL.0000000000000432","volume":"82","author":"R Ossenkoppele","year":"2014","unstructured":"Ossenkoppele R, et al. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology. 2014;82:1768\u201375.","journal-title":"Neurology"},{"key":"2085_CR30","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","volume":"75","author":"A de Wilde","year":"2018","unstructured":"de Wilde A, et al. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. JAMA Neurol. 2018;75:1062\u201370.","journal-title":"JAMA Neurol"},{"key":"2085_CR31","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.2967\/jnumed.114.139121","volume":"55","author":"MD Zwan","year":"2014","unstructured":"Zwan MD, et al. Comparison of simplified parametric methods for visual interpretation of 11\u00a0C-Pittsburgh compound-B PET images. J Nucl Med. 2014;55:1305\u20137.","journal-title":"J Nucl Med"},{"key":"2085_CR32","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","volume":"64","author":"BM Tijms","year":"2018","unstructured":"Tijms BM, et al. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-beta 1\u201342 Analysis Results. Clin Chem. 2018;64:576\u201385.","journal-title":"Clin Chem"},{"key":"2085_CR33","doi-asserted-by":"publisher","first-page":"e12182","DOI":"10.1002\/dad2.12182","volume":"13","author":"EAJ Willemse","year":"2021","unstructured":"Willemse EAJ, et al. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimers Dement (Amst). 2021;13:e12182.","journal-title":"Alzheimers Dement (Amst)"},{"key":"2085_CR34","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s11307-017-1080-z","volume":"19","author":"SSV Golla","year":"2017","unstructured":"Golla SSV, et al. Quantification of Tau Load Using [(18)F]AV1451 PET. Mol Imaging Biol. 2017;19:963\u201371.","journal-title":"Mol Imaging Biol"},{"key":"2085_CR35","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s11307-021-01581-5","volume":"23","author":"H Tuncel","year":"2021","unstructured":"Tuncel H, et al. Effect of Shortening the Scan Duration on Quantitative Accuracy of [(18)F]Flortaucipir Studies. Mol Imaging Biol. 2021;23:604\u201313.","journal-title":"Mol Imaging Biol"},{"key":"2085_CR36","doi-asserted-by":"crossref","unstructured":"Devous MD, Sr. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. J Nucl Med. 2018;59:937\u201343.","DOI":"10.2967\/jnumed.117.200691"},{"key":"2085_CR37","doi-asserted-by":"publisher","first-page":"944","DOI":"10.2967\/jnumed.117.200006","volume":"59","author":"S Southekal","year":"2018","unstructured":"Southekal S, et al. Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity. J Nucl Med. 2018;59:944\u201351.","journal-title":"J Nucl Med"},{"key":"2085_CR38","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/brain\/awz090","volume":"142","author":"MJ Pontecorvo","year":"2019","unstructured":"Pontecorvo MJ, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer\u2019s disease dementia. Brain. 2019;142:1723\u201335.","journal-title":"Brain"},{"key":"2085_CR39","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr., et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369.","journal-title":"Alzheimers Dement"},{"key":"2085_CR40","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher AS, et al. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol. 2020;77:829\u201339.","journal-title":"JAMA Neurol"},{"key":"2085_CR41","doi-asserted-by":"publisher","first-page":"e1850","DOI":"10.1212\/WNL.0000000000207794","volume":"101","author":"EM Coomans","year":"2023","unstructured":"Coomans EM, et al. Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies. Neurology. 2023;101:e1850\u201362.","journal-title":"Neurology"},{"key":"2085_CR42","doi-asserted-by":"publisher","first-page":"e70752","DOI":"10.1002\/alz.70752","volume":"21","author":"IMW Verberk","year":"2025","unstructured":"Verberk IMW, et al. Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer\u2019s disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium. Alzheimer\u2019s Dement. 2025;21:e70752.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2085_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, et al. Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat Reviews Neurol. 2024;20:426\u201339.","journal-title":"Nat Reviews Neurol"},{"key":"2085_CR44","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1214\/aos\/1013699998","volume":"29","author":"Y Benjamini","year":"2001","unstructured":"Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001;29:1165\u201388.","journal-title":"Ann Stat"},{"key":"2085_CR45","unstructured":"Verhage F. Intelligentie en leeftijd: Onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar. Van Gorcum\/Prakke & Prakke; 1964."},{"key":"2085_CR46","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.1002\/alz.14088","volume":"20","author":"IMW Verberk","year":"2024","unstructured":"Verberk IMW, et al. Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice. Alzheimers Dement. 2024;20:6115\u201332.","journal-title":"Alzheimers Dement"},{"key":"2085_CR47","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387\u201397.","journal-title":"Nat Med"},{"key":"2085_CR48","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20:739\u201352.","journal-title":"Lancet Neurol"},{"key":"2085_CR49","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26:379\u201386.","journal-title":"Nat Med"},{"key":"2085_CR50","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422\u201333.","journal-title":"Lancet Neurol"},{"key":"2085_CR51","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020;324:772\u201381.","journal-title":"JAMA"},{"key":"2085_CR52","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387\u201397.","journal-title":"Nat Med"},{"key":"2085_CR53","unstructured":"TauModification Drugs Take a Hit with Negative Trial. Alzforum. 2024. https:\/\/www.alzforum.org\/news\/conference-coverage\/tau-modification-drugs-take-hit-negative-trial."},{"key":"2085_CR54","unstructured":"ReardonS, Finally. Therapeutic Antibodies Start to Reduce Tangles. Alzforum. 2024. https:\/\/www.alzforum.org\/news\/conference-coverage\/finally-therapeutic-antibodies-start-reduce-tangles."},{"key":"2085_CR55","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s43856-025-00768-z","volume":"5","author":"A Feizpour","year":"2025","unstructured":"Feizpour A, et al. Alzheimer\u2019s disease biological PET staging using plasma p217\u2009+\u2009tau. Commun Med. 2025;5:53.","journal-title":"Commun Med"},{"key":"2085_CR56","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s43587-025-00835-z","volume":"5","author":"R Ossenkoppele","year":"2025","unstructured":"Ossenkoppele R, et al. Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials. Nat Aging. 2025;5:883\u201396.","journal-title":"Nat Aging"},{"key":"2085_CR57","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/alz.12875","volume":"19","author":"R Smith","year":"2023","unstructured":"Smith R, et al. Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. Alzheimers Dement. 2023;19:2497\u2013507.","journal-title":"Alzheimers Dement"},{"key":"2085_CR58","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13195-023-01302-w","volume":"15","author":"NS Mundada","year":"2023","unstructured":"Mundada NS, et al. Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment. Alzheimers Res Ther. 2023;15:157.","journal-title":"Alzheimers Res Ther"},{"key":"2085_CR59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-020-00713-3","volume":"13","author":"FH Duits","year":"2021","unstructured":"Duits FH, et al. Four subgroups based on tau levels in Alzheimer\u2019s disease observed in two independent cohorts. Alzheimers Res Ther. 2021;13:2.","journal-title":"Alzheimers Res Ther"},{"key":"2085_CR60","doi-asserted-by":"crossref","unstructured":"Horie K et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease. Nat Med. 2025.","DOI":"10.1038\/s41591-025-03617-7"},{"key":"2085_CR61","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s43587-023-00405-1","volume":"3","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya L, et al. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nat Aging. 2023;3:661\u20139.","journal-title":"Nat Aging"},{"key":"2085_CR62","doi-asserted-by":"publisher","first-page":"398","DOI":"10.14283\/jpad.2021.41","volume":"8","author":"J Cummings","year":"2021","unstructured":"Cummings J, et al. Aducanumab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2021;8:398\u2013410.","journal-title":"J Prev Alzheimers Dis"},{"key":"2085_CR63","unstructured":"Rogers MB. Donanemab Approval Likely to Pose New Quandaries for Clinicians. Alzforum; 2024."},{"key":"2085_CR64","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2023;10:362\u201377.","journal-title":"J Prev Alzheimers Dis"},{"key":"2085_CR65","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/alz.13609","volume":"20","author":"SM Landau","year":"2024","unstructured":"Landau SM, et al. Individuals with Alzheimer\u2019s disease and low tau burden: Characteristics and implications. Alzheimers Dement. 2024;20:2113\u201327.","journal-title":"Alzheimers Dement"},{"key":"2085_CR66","doi-asserted-by":"crossref","unstructured":"Pichet Binette A et al. Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease. JAMA Neurol. 2025;82(7):666\u2013675.","DOI":"10.1001\/jamaneurol.2025.1100"},{"key":"2085_CR67","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, et al. The AHEAD 3\u201345 Study: Design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:1227\u201333.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02085-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02085-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02085-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:24:41Z","timestamp":1789961081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02085-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2085"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02085-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants signed informed consent to use their medical data and biomaterials for research purposes. The study is approved by the medical ethical committee of the Amsterdam University Medical Centers (reference: 2017.315), and is conducted in accordance with ethical principles (Helsinki declaration 1975).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LK, EC, CT, AL have nothing to disclose. IV performs contract research with Roche Diagnostics and Sysmex. IV received speaker honoraria or consultancy fees from Quanterix, Olink and Neurogen Biomarking. All is paid directly to her institution. JH and LH are full time employees of ALZpath. As of 1-11-2025, WF is executive director at Alzheimer Nederland, Amersfoort the Netherlands. Before 1-11-2025, WF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. WF has been consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, Eisai, Eli-Lilly, Owkin France, Nationale Nederlanden Ventures. WF has participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. 2024-2025, WF has been member of the steering committee of phase 3 EVOKE\/EVOKE+ studies (NovoNordisk). In 2025, WF has been member of the steering committee op phase 3 Trontinemab study (Roche). All funding has been paid to Amsterdam UMC. WF was associate editor of Alzheimer, Research & Therapy in 2020\/2021. WF was associate editor at Brain 2021-2025. WF is chair of the Scientific Leadership Group of InRAD. WF is member of Supervisory Board (Raad van Toezicht) Trimbos Instituut. EV has received consultancy fees (paid to the institution) of New Amsterdam Pharma, Treeway, ReMynd, Vivoryon, Biogen, Vigil Neuroscience, ImmunoBrain Checkpoint, Muna Therapeutics, Esai, Eli Lilly, CogRX, Therini, UCB and Roche. Within his university affiliation he is PI of studies of DIAN, AC immune, Alnylam, CogRX therapeutics, New Amsterdam Pharma, Janssen, UCB, Roche, Vivoryon, ImmunoBrain, GSK, MSD, Biogen, Alector, Eli Lilly, AriBio Fuij Film Toyama, GemVax. EV is co-founder van het CANDIDATE Center Amsterdam UMC. EV collaborates on scientific projects with the Dutch Soccer Association (KNVB). RO is currently a full-time employee of Eli Lilly and Company. His contribution to the work presented in this manuscript was performed as an employee of Amsterdam University Medical Centers. RO has given lectures in symposia sponsored by GE Healthcare, received speaker fees from Springer, and was an advisory board\/steering committee member for Asceneuron, Biogen, Johnson & Johnson and Bristol Myers Squibb. All the aforementioned has been paid to Amsterdam University Medical Centers. EvdG has performed contract research for Heuron Inc., AC Immune and Roche. EvdG has a consultancy agreement with IXICO for reading PET scans. All support was paid to the institution. CT has research contracts with Acumen, ADx Neurosciences, AC-Immune, Alamar, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, C2N diagnostics, Celgene, Cognition Therapeutics, Danaher, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Instant Nano Biosensors, Merck, Muna, Nitrase Therapeutics, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Sysmex, Toyama, Vaccinex and Vivoryon. CT is editor in chief of Alzheimer Research and Therapy, and serves on editorial boards of Molecular Neurodegeneration, Alzheimer\u2019s & Dementia, Neurology: Neuroimmunology & Neuroinflammation, Medidact Neurologie\/Springer, and is committee member to define guidelines for Cognitive disturbances, and one for acute Neurology in the Netherlands. CT has consultancy\/speaker contracts for Aribio, Biogen, Beckman-Coulter, Cognition Therapeutics, Danaher, Eisai, Eli Lilly, Janssen, Merck, Neurogen Biomarking, Nordic Biosciences, Novo Nordisk, Novartis, Olink, Quanterix, Roche, Sanofi and Veravas.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"206"}}